The treatment of research and development (R&D) expenditures within the United States tax code is far more than an accounting technicality; it is a fundamental driver of where, how, and whether American corporations choose to innovate. As the global economy becomes increasingly interconnected, the tax treatment of R&D has become a central battleground for national competitiveness.
Under current U.S. law, the tax code creates a stark divide between domestic and foreign R&D expenditures. While domestic innovation benefits from flexible expensing options, foreign R&D is tethered to a rigid, 15-year amortization schedule. This divergence, intended by some to act as a lever for "onshoring," is increasingly viewed by economists as a self-defeating policy that threatens to undermine the very innovation it seeks to protect.
The Mechanics of the Divide: Section 174A vs. Section 174
At the heart of the debate is Section 174 of the Internal Revenue Code. Under Section 174A, U.S. taxpayers generally have a choice: they may either deduct domestic R&D costs immediately—providing a massive liquidity boost—or choose to amortize those costs over a period of at least 60 months. This flexibility is critical for firms experiencing net operating losses (NOLs), as it allows them to smooth deductions into future years when they can more effectively offset tax liabilities.
Conversely, foreign R&D is governed by a more restrictive interpretation of Section 174. There is no option for immediate expensing; firms are mandated to capitalize and amortize these expenses over 15 years. This effectively raises the "user cost of capital"—the hurdle rate a project must clear to be considered financially viable—for any R&D performed outside of U.S. borders.
A Chronology of Policy Shifts
The current regulatory environment is a relatively recent phenomenon. In the early 2020s, the United States briefly experimented with a uniform, mandatory amortization regime for all R&D, a move that drew widespread criticism from policy analysts and the Tax Foundation. The rationale for this earlier policy was to generate revenue, but the economic friction it created proved unsustainable.
Following intense pressure from the business community and innovation-heavy sectors, the One Big Beautiful Bill Act (OBBBA) reversed this mandate for domestic R&D, restoring the ability to expense. However, the legislation specifically excluded foreign R&D from this restoration. While the move was likely motivated by a desire to keep the budgetary cost of the OBBBA within manageable limits and to provide a "nudge" toward onshoring research operations, the exclusion has created a long-term structural disadvantage for U.S. multinational enterprises (MNEs).
Economic Foundations: Why Timing is Everything
To understand why the 15-year amortization schedule is so detrimental, one must look to the foundational work of economists Robert Hall and Dale Jorgenson. In their seminal 1967 research, Hall and Jorgenson established that the timing of tax deductions is not merely a matter of bookkeeping; it is a critical variable in investment behavior.
The Hall-Jorgenson Framework
In a tax-neutral regime characterized by "full expensing," the government essentially returns a portion of an investment’s cost to the firm upfront. According to the Hall-Jorgenson framework, when a firm can recover the full value of its investment in tax deductions immediately (the variable z equals 1), the tax component of the user cost of capital effectively cancels out. In such a scenario, the effective marginal tax rate on a "breakeven" investment—one that just barely covers its costs—is zero.
When the government forces a company to amortize costs over 15 years, it pushes z significantly below 1. This increases the hurdle rate for projects. If a project is on the cusp of being profitable, the tax burden imposed by mandatory amortization can turn a viable innovation into an abandoned project. By penalizing foreign R&D with a 15-year window, the U.S. tax code is essentially forcing U.S. companies to abandon or relocate projects that would have otherwise flourished.
The Myth of Substitution: Complementarity in Global R&D
A common argument among proponents of the current regime is that taxing foreign R&D more heavily will force companies to bring those jobs and research facilities back to the United States. However, this perspective ignores the complex reality of modern global supply chains and innovation networks.
Empirical evidence, including research from the Peterson Institute for International Economics (PIIE), suggests that international R&D is typically a complement to domestic activity, not a substitute. U.S. firms often invest in R&D abroad for two specific reasons:
- Market Adaptation: Products developed in the U.S. must often be tweaked to meet local regulatory standards, language requirements, or infrastructure specifications in foreign markets. This "localized" R&D allows U.S. products to be exported successfully.
- Access to Specialized Talent: Global firms often acquire foreign research teams or patents. Integrating these assets with the massive infrastructure and scale of a U.S. parent company often triggers further investment and job creation within the United States.
Economists like Gary Hufbauer and Theodore Moran have repeatedly warned that measures intended to hinder the globalization of R&D by U.S. firms do not "onshore" innovation; rather, they stifle it globally. When a U.S. firm is prevented from efficiently adapting its products for foreign markets, it loses market share to foreign competitors, which ultimately reduces the resources available for domestic research.
Implications: The M&A Disadvantage
The tax treatment of R&D has profound consequences for cross-border Mergers and Acquisitions (M&A). In a globalized market, U.S. firms are frequently in bidding wars for innovative startups or research-heavy targets.
If a U.S. firm acquires a foreign entity, it must contend with the 15-year amortization rule for that entity’s ongoing R&D. A foreign competitor, however, may be governed by a tax regime that allows for much faster expensing. Consequently, the U.S. firm’s after-tax valuation of the acquisition target is structurally lower.
The Semiconductor Industry Association (SIA) has raised alarms about this exact issue. As U.S. chip firms compete for global talent and IP, the tax code acts as a self-imposed barrier to growth. This effect is not limited to tech; the pharmaceutical industry, which relies heavily on high-stakes, long-term R&D, is similarly hampered. By making U.S. companies less competitive in the M&A space, the tax code inadvertently shrinks the global reach of the American corporate sector, reducing the total tax base and limiting the scale of domestic operations.
The Case for Neutrality
The current U.S. policy toward R&D represents a failure to understand the modern innovation ecosystem. By attempting to use the tax code to force a geographic relocation of research, policymakers have instead created a "tax trap" that diminishes the competitiveness of American firms.
Policy Recommendations
To foster a more robust, innovation-driven economy, the United States should pivot toward a neutral tax treatment of R&D. This includes:
- Equalizing Treatment: Aligning the treatment of foreign and domestic R&D, potentially through a universal expensing option that recognizes the time value of money.
- Reducing Competitive Disadvantage: Eliminating the mandatory 15-year amortization window, which artificially raises the hurdle rate for essential global research.
- Focusing on Global Competitiveness: Recognizing that R&D is an interdependent process. Policies that promote the expansion of U.S. firms globally are, by extension, policies that support the growth of their domestic headquarters.
As the global race for technological supremacy intensifies, the United States cannot afford to let outdated accounting policies dictate its economic future. By moving toward a neutral, efficient tax regime, the U.S. can ensure that its companies remain the primary drivers of global innovation, regardless of where that research occurs. The objective should not be to artificially constrain where R&D happens, but to ensure that the U.S. tax code supports the most efficient, high-value investment paths possible. Only by shedding these structural burdens can American firms maintain their status as the world’s most dynamic innovators.
